An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

Recruiting now · Phase 1

Conditions studied: Myeloid Malignancy

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.

Key facts

Study ID

NCT07619287

Run by

BeOne Medicines

People needed

118

Starts

2026-06-23

Expected to finish

2028-09-30

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF).
• Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories:
• Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable/inaccessible, or declined by patient.
• Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

You may not qualify if…

• Prior exposure to KAT6A/B inhibitors/degraders.
• A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia.
• Known central nervous system involvement by leukemia
• Use of antileukemic therapies without sufficient washout period
• Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it is running

• Concord Repatriation General Hospital — Concord, New South Wales, Australia (enrolling)
• St George Hospital — Kogarah, New South Wales, Australia (enrolling)
• Icon Cancer Centre Kurralta Park — Kurralta Park, South Australia, Australia (enrolling)
• Linear Clinical Research — Nedlands, Western Australia, Australia (enrolling)
• The First Hospital of Lanzhou University — Lanzhou, Gansu, China (enrolling)
• The Second Hospital of Hebei Medical University — Shijiazhuang, Hebei, China (enrolling)
• The First Affiliated Hospital of Nanchang University Branch Donghu — Nanchang, Jiangxi, China (enrolling)
• The First Affiliated Hospital of Nanchang University Branch Xianghu — Nanchang, Jiangxi, China (enrolling)
• Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch — Tianjin, Tianjin Municipality, China (enrolling)
• Auckland City Hospital — Auckland, New Zealand (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.